Luminex (LMNX) Rallies On FDA Nod For Aries M1 System
Zacks Investment Research | Jul 07, 2016 06:25AM ET
Luminex Corp. (NASDAQ:LMNX) recently announced FDA approval for the Aries M1 system. Notably, the share price of Luminex gained almost 3% to close at $20.92, following the go-ahead.
The system has also gained a CE-IV(D) status under the European Directive on In-Vitro Diagnostic Medical Devices. Aries M1 system will be unveiled by the end of July this year.
Notably, M1 systems are specifically designed for seamless operations in limited service small satellite laboratories. The system provides a highly integrated platform to perform PCR Assays (Polymerase Chain Reaction tests) which delivers accurate results and increased lab efficiency.
The M1 system is a simplified version of Luminex’s well-known Aries system. It has noteworthy features like intuitive system interface, STAT or batch testing and true walkaway capability that enhance the utility of smaller labs.
Aries M1 functions in three major stages – extraction, amplification and detection of nucleic acids from a broad array of samples. Notably, the system can process up to six different samples and work upon one to six assays at a single time. We believe Aries M1 is a minimally erroneous platform in the space as the system involves least technical intervention while delivering final results.
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.